Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Thol

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Der Internist|November 7, 2019
[What is recommended in the treatment of acute myeloid leukemia?]F Thol
Der Internist|February 22, 2015
[Myelodysplastic syndromes]F Thol, M Heuser, A Ganser
The Journal of Craniofacial Surgery|March 16, 2026
Postoperative Pain Management in Orthognathic Surgery: Is There a Need for Opioids?P D Stoll, F Thol, N Spuck, et al.
Annals of Hematology|May 8, 2014
Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysisM Port, M Böttcher, F Thol, et al.
Leukemia|June 8, 2011
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groupsF Damm, F Thol, I Hollink, et al.
Leukemia|May 8, 2013
SETBP1 mutation analysis in 944 patients with MDS and AMLF Thol, K J Suchanek, C Koenecke, et al.
Leukemia|August 10, 2011
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemiaF Damm, T Bunke, F Thol, et al.
Leukemia|May 23, 2014
Low frequency of calreticulin mutations in MDS patientsM Heuser, V Panagiota, C Koenecke, et al.
Leukemia|April 12, 2016
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarateA Chaturvedi, M M Araujo Cruz, N Jyotsana, et al.
Leukemia|August 30, 2012
Analysis of NUP98/NSD1 translocations in adult AML and MDS patientsF Thol, B Kölking, I H I Hollink, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Der Internist|November 7, 2019
[What is recommended in the treatment of acute myeloid leukemia?]F Thol
Der Internist|February 22, 2015
[Myelodysplastic syndromes]F Thol, M Heuser, A Ganser
The Journal of Craniofacial Surgery|March 16, 2026
Postoperative Pain Management in Orthognathic Surgery: Is There a Need for Opioids?P D Stoll, F Thol, N Spuck, et al.
Annals of Hematology|May 8, 2014
Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysisM Port, M Böttcher, F Thol, et al.
Leukemia|June 8, 2011
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groupsF Damm, F Thol, I Hollink, et al.
Leukemia|May 8, 2013
SETBP1 mutation analysis in 944 patients with MDS and AMLF Thol, K J Suchanek, C Koenecke, et al.
Leukemia|August 10, 2011
Prognostic implications and molecular associations of NADH dehydrogenase subunit 4 (ND4) mutations in acute myeloid leukemiaF Damm, T Bunke, F Thol, et al.
Leukemia|May 23, 2014
Low frequency of calreticulin mutations in MDS patientsM Heuser, V Panagiota, C Koenecke, et al.
Leukemia|April 12, 2016
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarateA Chaturvedi, M M Araujo Cruz, N Jyotsana, et al.
Leukemia|August 30, 2012
Analysis of NUP98/NSD1 translocations in adult AML and MDS patientsF Thol, B Kölking, I H I Hollink, et al.
Pageof 3